New River reiterated by Merrill at buy

New River Pharmaceuticals Inc. was reiterated by Merrill Lynch analyst David Munno at a buy rating with a price target on the stock of $49 per share following a non-deal roadshow. Merrill believes New River, no longer a one-product company, could continue to provide value despite recent price appreciation. New River shares Tuesday were down $1.94, or 4.85%, at $38.06 on volume of 148,634 shares versus the three-month running average of 53,049.2 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.